Celcuity Inc.

ATTORNEYS

CONTACT

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Celcuity announced on July 14, 2026, that it had received FDA approval for its breast cancer treatment Revtorpyk (gedatolisib), adding that it “anticipates commercial launch in late Q3 2026,” a delayed timeframe compared to analyst expectations. Based on this news, shares of Celcuity fell by 17.6% on the next day.

PRESS RELEASE

"*" indicates required fields

Comments

This field is for validation purposes and should be left unchanged.

Email Address*

Phone Number **

Please upload a list of your transactions or manually enter them below

Drop files here or

Accepted file types: xls, xlsx, doc, pdf, jpg, jpeg, Max. file size: 2 GB, Max. files: 5.

You may redact your account numbers from your uploaded documents. The Schall Law Firm is committed to protecting the privacy of confidential information. Your documents will be securely held in AWS S3 and will only be used as proof of your transactions in connection with this matter.

Purchases

Purchase Dates

Number of Shares

Price Per Share

If fractional shares, please round to the nearest whole number.

Sales

Sales Dates

Number of Shares

Price Per Share

How did you hear about this case?*

Are you a current or former employee of the company?*

Yes

Would you like to receive case and litigation updates from The Schall Law Firm via e-mail?*

Yes

If you would like to provide additional information regarding your amount of loss or your investment (i.e. type of security purchased), please do so below.

By submitting your information, you acknowledge that this form does not create an attorney-client relationship between yourself and The Schall Law Firm. Any information you submit will be maintained as confidential. The Schall Law Firm, in its sole discretion, will contact you if it requires further information from you.